Figure 4.
Treatment durations with abivertinib and sequential osimertinib in nine patients. (
) PFS with abivertinib, (
) PFS with osimertinib, (
) disease progression, (
) treatment ongoing and (
) switch because of adverse effect.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.